Rong Deng, Leonid Gibiansky, Tong Lu, Christopher R Flowers, Laurie H Sehn, Qi Liu, Priya Agarwal, Michael Z Liao, Randall Dere, Calvin Lee, Gabriel Man, Jamie Hirata, Chunze Li, Dale Miles
Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that targets B cells and delivers the cytotoxic payload monomethyl auristatin E (MMAE). The phase III POLARIX study (NCT03274492) evaluated polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) as first-line treatment of diffuse large B-cell lymphoma (DLBCL). To examine dosing decisions for this regimen, population pharmacokinetic (popPK) analysis, using a previously developed popPK model, and exposure-response (ER) analysis, were performed...
April 15, 2024: CPT: Pharmacometrics & Systems Pharmacology